ArticlePLoS neglected tropical diseases2012
Enhanced protective efficacy of a chimeric form of the schistosomiasis vaccine antigen Sm-TSP-2.
Article in PLoS neglected tropical diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 88 citations in OpenAlex.
- Optimization and production of a GLP-grade recombinant Sm29 vaccine against schistosomiasis: From expression to preclinical assessment.PLoS neglected tropical diseases · 2026Article
- mRNA vaccines encoding variant forms of Sm-TSP-2 confer protective immunity against Schistosoma mansoni.NPJ vaccines · 2025Article
- Schistosoma japonicum cathepsin L1: A potential target for anti-schistosomiasis strategies.PLoS neglected tropical diseases · 2025Article
- Pre-clinical studies of Schistosoma mansoni vaccines: A scoping review.PLoS neglected tropical diseases · 2025Article
- A Krüppel-like factor establishes cellular heterogeneity during schistosome tegumental maintenance.PLoS pathogens · 2025Article
- Molecular characterization and B-cell epitope analysis of the TSP11 gene inParasitology · 2024Article
- A Krüppel-like factor establishes cellular heterogeneity during schistosome tegumental maintenance.bioRxiv : the preprint server for biology · 2024Article
- The efficacy of cercarial antigen loaded on nanoparticles as a potential vaccine candidate inJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024Article
- Schistosoma mansoni vaccine candidates identified by unbiased phage display screening in self-cured rhesus macaques.NPJ vaccines · 2024Article
- Therapeutic and vaccinomic potential of moonlighting proteins for the discovery and design of drugs and vaccines against schistosomiasis.American journal of translational research · 2024Review
- Schistosoma japonicum EKLF/KLF1 is a potential immune target to tackle schistosomiasis.Parasites & vectors · 2023Article
- Advances in new target molecules against schistosomiasis: A comprehensive discussion of physiological structure and nutrient intake.PLoS pathogens · 2023Review
- Vaccines for Human Schistosomiasis: Recent Progress, New Developments and Future Prospects.International journal of molecular sciences · 2022Review
- Characterisation of tetraspanins from Schistosoma haematobium and evaluation of their potential as novel diagnostic markers.PLoS neglected tropical diseases · 2022Article
- Immunomics-guided discovery of serum and urine antibodies for diagnosing urogenital schistosomiasis: a biomarker identification study.The Lancet. Microbe · 2021Article
- Evaluation of Immunogenicity and Efficacy ofVaccines · 2021Article
- Recent Advances and Methodological Considerations on Vaccine Candidates for Human Schistosomiasis.Frontiers in tropical diseases · 2021Article
- Immunological Considerations forFrontiers in immunology · 2021Review
- Robust Immune Response Induced byInternational journal of nanomedicine · 2021Article
- Current status and future prospects of protein vaccine candidates againstParasite epidemiology and control · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The large extracellular loop of the Schistosoma mansoni tetraspanin, Sm-TSP-2, when fused to a thioredoxin partner and formulated with Freund's adjuvants, has been shown to be an efficacious vaccine against murine schistosomiasis. Moreover, Sm-TSP-2 is uniquely recognised by IgG(1) and IgG(3) from putatively resistant individuals resident in S. mansoni endemic areas in Brazil. In the present study, we expressed Sm-TSP-2 at high yield and in soluble form in E. coli without the need for a solubility enhancing fusion partner. We also expressed in E. coli a chimera called Sm-TSP-2/5B, which consisted of Sm-TSP-2 fused to the immunogenic 5B region of the hookworm aspartic protease and vaccine antigen, Na-APR-1. Sm-TSP-2 formulated with alum/CpG showed significant reductions in adult worm and liver egg burdens in two separate murine schistosomiasis challenge studies. Sm-TSP-2/5B afforded significantly greater protection than Sm-TSP-2 alone when both antigens were formulated with alum/CpG. The enhanced protection obtained with the chimeric fusion protein was associated with increased production of anti-Sm-TSP-2 antibodies and IL-4, IL-10 and IFN-γ from spleen cells of vaccinated animals. Sera from 666 individuals from Brazil who were infected with S. mansoni were screened for potentially deleterious IgE responses to Sm-TSP-2. Anti-Sm-TSP-2 IgE to this protein was not detected (also shown previously for Na-APR-1), suggesting that the chimeric antigen Sm-TSP-2/5B could be used to safely and effectively vaccinate people in areas where schistosomes and hookworms are endemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.